BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1352 related articles for article (PubMed ID: 29749524)

  • 1. Multifaceted regulation and functions of YAP/TAZ in tumors (Review).
    Liu H; Du S; Lei T; Wang H; He X; Tong R; Wang Y
    Oncol Rep; 2018 Jul; 40(1):16-28. PubMed ID: 29749524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
    Kim M; Kim T; Johnson RL; Lim DS
    Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
    Zhu J; Wu T; Lin Q
    Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
    Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
    Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 9. Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.
    Ando T; Charindra D; Shrestha M; Umehara H; Ogawa I; Miyauchi M; Takata T
    Oncogene; 2018 Jan; 37(2):263-270. PubMed ID: 28925394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research advances in the role of the Hippo-YAP/TAZ signaling pathway in primary liver cancer].
    Guo LW; Shao GL
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):878-880. PubMed ID: 29325286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
    Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
    Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging roles of YAP and TAZ in cancer.
    Moroishi T; Hansen CG; Guan KL
    Nat Rev Cancer; 2015 Feb; 15(2):73-79. PubMed ID: 25592648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization.
    Yoo G; Kim T; Chung C; Hwang DS; Lim DS
    Biochem Biophys Res Commun; 2017 Aug; 490(3):650-656. PubMed ID: 28634071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
    Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
    J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into the ambivalent role of YAP/TAZ in human cancers.
    Luo J; Deng L; Zou H; Guo Y; Tong T; Huang M; Ling G; Li P
    J Exp Clin Cancer Res; 2023 May; 42(1):130. PubMed ID: 37211598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1.
    Janse van Rensburg HJ; Azad T; Ling M; Hao Y; Snetsinger B; Khanal P; Minassian LM; Graham CH; Rauh MJ; Yang X
    Cancer Res; 2018 Mar; 78(6):1457-1470. PubMed ID: 29339539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.
    Li H; Gumbiner BM
    Mamm Genome; 2016 Dec; 27(11-12):556-564. PubMed ID: 27601049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 68.